

Subject: Specialised Services Circular (SSC)

Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
2777	NHS England Clinical Commissioning Algorithm: Hereditary and Acquired Angioedema	University Hospital Bristol and Weston North Bristol Trust University Hospital Plymouth

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? **No**

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

All Chief Executives

All Medical Directors

All Chief Pharmacists

Specialised Commissioning South West
NHS England
100 Temple Street
Bristol
BS1 6AG
Email: england.speccomm-southwest@nhs.net

14 February 2025

Dear Colleagues,

Re: NHS England Clinical Commissioning Algorithm: Hereditary and Acquired Angioedema

I am writing to advise you that an NHS England Clinical Commissioning Algorithm for Hereditary and Acquired Angioedema has been published.

The Algorithm can be found at <https://www.england.nhs.uk/wp-content/uploads/2025/02/hereditary-amd-acquired-angioedema-algorithms.pdf>

The Algorithm describes the key criteria for accessing commissioned treatments in line with the previously published NICE TAs and NHS England Clinical Commissioning Policies:

- Berotralstat for preventing recurrent attacks of hereditary angioedema (Technology appraisal guidance [TA738]) SSC 2313 (2021) <https://www.nice.org.uk/guidance/ta738>
- Lanadelumab for preventing recurrent attacks of hereditary angioedema (Technology appraisal guidance [TA606]) SSC 2110 (2019) <https://www.nice.org.uk/guidance/ta606>
- Clinical Commissioning Policy: Treatment of Acute Attacks in Hereditary Angiodema (Adult)(April 2013) <https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2013/09/b09-p-b.pdf>
- Clinical Commissioning Policy: Plasma-derived C1-esterase inhibitor for prophylactic treatment of hereditary angioedema (HAE) types I and II SSC 1658 (2016) https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2013/05/16045_FINAL.pdf

The Algorithm provides a framework to aid decision making for angioedema specialists and patients.

In addition:


- Trusts must ensure that they are purchasing commissioned therapies at the agreed patient access scheme (PAS) discounted or framework price. This discounted price will be applied automatically at point of invoice and applies to all indications.

- The discounted price paid by Trusts remains the same as the existing discounted price
- Trusts must ensure that only invoices for the drug procurement costs of treatments for this indication are invoiced to NHSE. All other on costs are in block arrangements.
- In line with the terms and conditions included in the NHS Standard Contract and as per the agreement that Cancer Services are commissioned with Trusts, Schedule 6a Reporting Requirements for drugs will apply. Payment of Trust invoices will be contingent on the completion of the MDS record and this information being made available in a timely way.
- Patients must be registered via Blueteq and meet the clinical criteria on the registration form.
- **Payment of Trust invoices will be contingent on Blueteq registration and MDS record being completed and this information being made available in a timely way.**
- Trusts must ensure that local governance aspects (e.g. technical issues, education & training, patient information) have been identified and addressed for all staff groups (as appropriate) in order to permit the safe delivery of this therapy.

Trusts should refer to the CAP portal for further information on the PAS price. The CAP portal is available at <https://nhsengland.sharefile.eu/Authentication/Login>

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent application of commissioned treatments.

With best wishes,



Emma Redfern
Medical Director NHS England South West
Region



Tracey Williams
Principal Pharmacist